HC Wainwright Issues Pessimistic Outlook for ORIC Earnings
HC Wainwright has revised down its earnings per share forecasts for Oric Pharmaceuticals (NASDAQ:ORIC) for Q3 2026 and FY2026, projecting larger losses. Despite the more pessimistic outlook, HC Wainwright maintained a "Buy" rating and a $27 price target on the stock. Oric Pharmaceuticals recently missed its Q2 earnings consensus, reporting a loss of $0.38 per share against an estimate of $0.36.
Understanding Momentum Shifts in (ORIC)
This article provides an analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on momentum shifts and potential trading strategies based on AI models. It highlights strong near and mid-term sentiment, identifies compelling upside potential due to the absence of resistance levels, and offers specific position, momentum breakout, and risk hedging trading strategies. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25
H.C. Wainwright has raised its target price for ORIC Pharmaceuticals, Inc. from $25 to $27. This adjustment suggests a positive outlook from the analytical firm regarding the company's future performance. The news was reported by Reuters.
ORIC Pharmaceuticals, Inc. (ORIC) options chain
This article provides the options chain for ORIC Pharmaceuticals, Inc. (ORIC), including call and put options with various strike prices and expiration dates. It details last trade dates, prices, bids, asks, volume, open interest, and implied volatility for contracts expiring on February 19, 2027. The current stock price of ORIC is reported as $13.96, up 1.68%.
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ
The article displays the "Price to book forward" for Oric Pharmaceuticals, Inc. (HAM:4TZ) on the Hamburg Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content provides a snapshot of financial data related to this specific company.
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25
H.C. Wainwright has increased its target price for ORIC PHARMACEUTICALS, INC. (ORIC.O) from $25 to $27. This update was reported by Reuters and indicates a positive adjustment in the analyst's valuation of the pharmaceutical company.
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally
ORIC Pharmaceuticals (ORIC) has garnered attention after reporting Q2 2026 results, showing wider net losses but improved basic loss per share, alongside significant share price momentum. The company's price-to-book ratio of 3.7x is below its direct peer average but above the broader US Biotechs industry average, indicating mixed market valuation signals. Despite being unprofitable and forecasting continued losses, the current valuation reflects expectations stronger than the sector but more cautious than its direct peer group.
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress
H.C. Wainwright increased its price target for ORIC Pharmaceuticals (NASDAQ:ORIC) to $27 from $25, maintaining a Buy rating, citing a catalyst-rich second half of 2026 for the biopharmaceutical company. ORIC is expected to provide updates on its ORIC-944 program and present new data for enozertinib in various non-small cell lung cancer treatments. This positive outlook follows other analyst coverage and a recent upgrade from Goldman Sachs, highlighting ORIC's progress in its pipeline, particularly with its lead asset, rinzimetostat.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has received a "Moderate Buy" consensus recommendation from sixteen brokerages, with an average 12-month price target of $19.27. Despite missing its last quarterly earnings estimate, institutional investors hold a significant portion of ORIC shares, and several research firms have recently updated their ratings, mostly positively. The company, a clinical-stage biopharmaceutical firm, focuses on developing small molecule therapeutics for solid tumor oncology.
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) announced inducement grants to two new employees. These grants include non-statutory stock options to purchase 32,500 shares of common stock and restricted stock units (RSUs) representing the right to receive 15,000 shares of common stock. The grants were made as an inducement material to the employees entering employment with ORIC, in compliance with Nasdaq Listing Rule 5635(c)(4).
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC
Dimensional Fund Advisors LP significantly increased its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 19.9% in the first quarter, bringing its total holdings to 1.47 million shares valued at $18.6 million. Institutional investors now collectively own 95.05% of the company. Despite the positive institutional interest and a "Moderate Buy" average analyst rating with a target price of $19.27, Oric Pharmaceuticals reported a quarterly loss of $0.38 per share, missing consensus estimates, and analysts anticipate a full-year loss of $1.49 per share.
Price to book forward of Oric Pharmaceuticals, Inc. – SWB:4TZ
This article provides a financial snapshot for Oric Pharmaceuticals, Inc. (SWB:4TZ) on the Stuttgart Stock Exchange. It specifically highlights the "Price to book forward" metric. The article is brief and presents no specific financial values but confirms the market is closed with no trades.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants of non-qualified stock options and restricted stock units to five new non-executive employees, effective August 3, 2026. These grants, totaling 125,400 stock options and 20,550 restricted stock units, were approved by the Compensation Committee of the Board of Directors under Nasdaq Rule 5635(c)(4) as a material inducement to employment. The vesting schedules for these grants are detailed, with stock options vesting over four years and restricted stock units over three years.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to five new non-executive employees, including 125,400 non-qualified stock options and 20,550 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made on August 3, 2026, as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). The company specializes in developing treatments to overcome therapeutic resistance in cancer, with product candidates like rinzimetostat and enozertinib.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to five new non-executive employees, consisting of 125,400 non-qualified stock options and 20,550 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made on August 3, 2026, as a material inducement for employment and are subject to specific vesting schedules. The company also provided an overview of its clinical-stage oncology product candidates.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses but improving per-share losses in the second quarter and first half of 2026, primarily due to a larger share count. The company remains a high-risk biotech story, relying on its oncology pipeline and continued equity financing, with future clinical trial results acting as key catalysts. Investors face potential dilution risks and a wide range of fair value estimates, highlighting the speculative nature of the investment.
Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Evercore ISI analyst Cory Kasimov has maintained a Buy rating on Oric Pharmaceuticals (ORIC) with a price target of $25.00. Kasimov has a strong track record in the Healthcare sector, and Oric Pharmaceuticals holds a consensus "Strong Buy" rating from analysts. The company recently reported a quarterly GAAP net loss of $41.49 million for the quarter ending June 30.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses in Q2 and the first half of 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, the company saw improved basic and diluted loss per share due to a larger share count. The article suggests that equity remains the primary funding mechanism for the high-risk biotech firm, with clinical trial execution being the near-term catalyst.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses for Q2 and H1 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, basic and diluted loss per share improved to US$0.38 and US$0.72 for the same periods, primarily due to a larger share count. The company's investment narrative remains that of a high-risk biotech heavily reliant on its oncology pipeline, with future dilution and clinical trial success being key factors for investors.
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% Higher - Here's What Happened
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares rise by 12.3% in midday trading on Tuesday, despite a significant drop in trading volume and a recent earnings miss. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $19.27, and institutional investors hold a substantial 95.05% of its stock.
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC)
Traders purchased a significantly high volume of put options on Oric Pharmaceuticals (NASDAQ:ORIC), indicating bearish sentiment or a desire for downside protection. This activity occurred despite the company's shares rising and analysts maintaining a "Moderate Buy" consensus rating with an average target price of $19.27. Institutional investors hold a substantial portion of the company's stock.
ORIC Starts Global Prostate Cancer Trial Expected to Enroll About 600
ORIC Pharmaceuticals reported its Q2 2026 financial results, highlighting the initiation of the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), which is expected to enroll approximately 600 patients. The company also announced a collaboration with Bayer for the trial and stated that its cash and investments of $387.6 million are expected to fund operations into the second half of 2028. Despite a net loss of $41.5 million in Q2, ORIC emphasized its advancement into a diversified, late-stage oncology company.
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary
Oric Pharmaceuticals, Inc. reported a wider net loss of $(77.3M) for the six months ended June 30, 2026, compared to $(66.4M) in the previous year, primarily due to ongoing R&D investments. Despite the increased net loss, diluted loss per share improved to $(0.72) from $(0.89). The company advanced lead clinical programs, entered collaborations, and adjusted its operational focus by reducing its workforce to extend its funding runway into the second half of 2028.
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary
Oric Pharmaceuticals, Inc. reported a wider net loss of $(77.3M) for the six months ended June 30, 2026, compared to $(66.4M) in the prior-year period, driven by continued R&D investment. Despite the increased net loss, diluted loss per share improved to $(0.72) from $(0.89). The company highlighted progress in its clinical pipeline, including advancing rinzimetostat to Phase 3 and enozertinib for a potential Phase 3 dose, and has secured funding to support operations into the second half of 2028.
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals announced its second quarter 2026 financial results and operational updates, including the initiation of the Himalayas-1 global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC). The company also reported a clinical trial collaboration with Bayer for darolutamide and anticipates program updates for rinzimetostat and enozertinib in the second half of 2026. ORIC expects its cash and investments of approximately $388 million to fund operations into the second half of 2028.
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% - Should You Sell?
Oric Pharmaceuticals (NASDAQ:ORIC) saw its stock price fall by 5.2% on Monday, trading at around $10.50, with trading volume significantly below average. Despite missing its latest quarterly earnings estimates, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price target of $19.27. Institutional investors hold a substantial 95.05% stake in the clinical-stage biopharmaceutical company.
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals (Nasdaq: ORIC) reported its second quarter 2026 financial results, highlighting the initiation of the Himalayas-1 global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) and a collaboration with Bayer for darolutamide supply. The company anticipates program updates for rinzimetostat and enozertinib in the second half of 2026. ORIC expects its cash and investments of $387.6 million to fund operations into the second half of 2028.
Defilade Capital Management L.P. Purchases Shares of 842,928 Oric Pharmaceuticals, Inc. $ORIC
Defilade Capital Management L.P. has acquired a new stake of 842,928 shares in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), valued at approximately $10.68 million, making it about 1.5% of their portfolio. Institutional investors collectively own 95.05% of the company, with many increasing their positions recently. Despite Oric Pharmaceuticals missing its latest quarterly EPS estimate, analysts maintain a "Moderate Buy" rating with an average price target of $19.27.
Avoiding Lag: Real-Time Signals in (ORIC) Movement
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting a mid-channel oscillation pattern with strong near and mid-term sentiment but a weak long-term outlook. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The article highlights an exceptional 83.7:1 risk-reward setup targeting a 25.2% gain versus 0.3% risk.
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 77.77% Potential Upside Beckons Biotech Investors
Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company with a potential upside of 77.77% according to analyst ratings. The company focuses on developing therapies to combat cancer resistance, with key candidates enozertinib and rinzimetostat in Phase 1b studies and strategic collaborations with Bayer and Johnson & Johnson. Despite being pre-revenue with negative free cash flow, analyst sentiment is overwhelmingly positive, with an average target price of $20.69.
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC
Vivo Capital LLC reduced its stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 12.7% in the first quarter, selling 269,598 shares but still holding 1.85 million shares valued at $23.4 million. Despite institutional investors owning 95.05% of ORIC, the company reported a quarterly loss that missed estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $19.27.
Oric Pharmaceuticals expands 2022 inducement equity plan share pool by 1,100,000 shares
Oric Pharmaceuticals has expanded its 2022 Inducement Equity Incentive Plan by 1,100,000 shares, increasing the total to 3,350,000 common shares. This amendment, effective July 28, 2026, aims to support equity awards for new hires or grants related to mergers and acquisitions. The information was generated by AI based on content published by Oric Pharmaceuticals Inc. via EDGAR.
ETFs Investing in Oric Pharmaceuticals, Inc. Stocks
This article lists various ETFs that hold stocks of Oric Pharmaceuticals, Inc., detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment strategies and market segments, from health care and biotechnology to small-cap and micro-cap, offering investors diversified exposure to Oric Pharmaceuticals.
Oric Pharmaceuticals (ORIC) director trades options, sells 13,100 shares
Oric Pharmaceuticals director Richard A. Heyman exercised stock options for 3,500 shares at $1.60 per share and subsequently sold 13,100 common shares at $12.02 per share on July 24, 2026. These sales, which included shares held through RAHD Capital, LLC, were executed under a Rule 10b5-1 trading plan. After these transactions, Heyman retained voting and investment power over 206,672 indirect shares and 30,200 outstanding options.
Oric Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ORIC
This article provides an overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) financial information, specifically focusing on its revenue breakdown. It includes links to various financial statements, statistics, dividend information, and earnings reports. The content is presented as part of a financial data platform, likely TradingView, offering tools for market analysis.
ORIC|Oric Pharmaceuticals Inc|Price:11.710|Chg%:+0.070
Oric Pharmaceuticals Inc. (ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies to overcome cancer resistance. The company has a diverse pipeline, including clinical-stage product candidates ORIC-944 for prostate cancer and ORIC-114 for genetically defined cancers, alongside multiple discovery stage precision medicines. As of 2026Q1, 343 institutions hold shares, with institutional shareholding increasing by over 8.8 million compared to 2025Q4.
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
The article provides a technical analysis of Oric Pharmaceuticals Inc (ORIC), examining various indicators and moving averages. It summarizes the current signals, noting a neutral signal based on moving averages and other technical indicators, with six buy signals from moving averages MA5 to MA200. The analysis emphasizes that technical analysis is for reference only and not an absolute standard for investment decisions.
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC
Orbimed Advisors LLC reduced its stake in Oric Pharmaceuticals by 26% in the first quarter of 2026, selling 947,827 shares but still retaining 2.69 million shares valued at approximately $34.1 million. Despite a quarterly loss exceeding analyst expectations, Oric Pharmaceuticals maintains a "Moderate Buy" consensus rating from analysts with an average price target of $19.27. Oric Pharmaceuticals is a clinical-stage oncology biotech company focused on developing treatments to overcome resistance to cancer therapies.
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Oric Pharmaceuticals Inc (ORIC) based on various financial metrics. It details the company's volatility, daily returns, Sharpe ratio, maximum drawdown, and liquidity. The report offers investors a comprehensive statistical overview of ORIC's risk profile.
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210
This article provides a detailed explanation of TradingKey's comprehensive stock scoring system for Oric Pharmaceuticals Inc (ORIC), despite indicating that no score is currently available due to insufficient data. It outlines how various scores are generated, including financial health, company valuation, earnings forecast, price momentum, institutional confidence, and risk management, by analyzing numerous financial indicators, market data, and expert assessments. The information aims to help investors make more informed decisions by providing a thorough analysis of the company's performance and outlook.
Oric Pharmaceuticals Inc (ORIC) Balance Sheet
This article provides a detailed balance sheet for Oric Pharmaceuticals Inc (ORIC), presenting quarterly and annual financial data spanning several years. It includes key financial metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity, along with year-over-year percentage changes. The page also offers an FAQ section addressing common questions about balance sheet analysis for ORIC stock.
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy?
Oric Pharmaceuticals (ORIC) has initiated a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, retaining full development and commercial rights while Bayer supplies a key drug at no cost. This strategy positions ORIC as a high-risk, pre-revenue biotech with significant clinical and financial uncertainties, despite the potential for a key catalyst from the trial. Investors are urged to consider the high cash burn, valuation risks, and binary clinical outcomes associated with this approach.
Oric Pharmaceuticals Inc (ORIC) Cash Flow
This article provides a detailed cash flow statement for Oric Pharmaceuticals Inc (ORIC), including operating, investing, and financing cash flows presented quarterly and annually. It highlights key financial figures such as net income from continuing operations, capital expenditures, and free cash flow over several fiscal years. The article also includes an FAQ section explaining different types of cash flow and how to interpret ORIC's specific cash flow figures.
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence
The article provides an overview of Oric Pharmaceuticals Inc. (ORIC) with a focus on its institutional confidence, highlighting major institutional shareholders and their recent activity. Key investors like Nextech Invest, EcoR1 Capital, and Viking Global Investors are listed with their shareholdings, alongside the company's market capitalization and recent stock performance.
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210
Oric Pharmaceuticals Inc. (ORIC) closed at $12.100, up 11.11%, with a market capitalization of $1.25 billion. The company, which focuses on oncology drugs, has a "Buy" analyst rating with a target price of $20.545, indicating an 88.66% upside. Technical indicators show mixed signals, with several moving averages suggesting a "Buy" trend.
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen
Wall Street Zen upgraded Oric Pharmaceuticals (NASDAQ:ORIC) from a "strong sell" to a "sell" rating. Despite this, the stock holds a "Moderate Buy" consensus from other analysts with an average target price of $19.27. Oric Pharmaceuticals saw an 11.1% gain in Friday trading but missed its Q1 earnings expectations, with analysts now forecasting a -1.45 EPS for the current year.
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4% - Time to Buy?
Oric Pharmaceuticals (NASDAQ:ORIC) saw its stock price rise 5.4% on Friday, trading at $11.4820 with lower-than-average volume. Despite an average "Moderate Buy" rating and a $19.27 consensus price target from analysts, the clinical-stage biopharmaceutical firm recently reported a quarterly EPS loss of $0.34, missing expectations. Institutional investors have been active, with significant increases in holdings by firms like Bank of America Corp DE and The Manufacturers Life Insurance Company.
Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC
Siren L.L.C. significantly increased its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 197.6% in the first quarter, now holding 2.99 million shares valued at approximately $37.99 million. Other institutional investors also adjusted their positions, with overall institutional ownership reaching 95.05%. Analysts have a "Moderate Buy" consensus rating with a target price of $19.27, despite some recent rating and target price adjustments.
Discipline and Rules-Based Execution in ORIC Response
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting mixed sentiment across time horizons, indicating potential choppiness. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop levels, targeting an exceptional 81.7:1 risk-reward setup. Investors are advised to consult current signals for optimal positioning and risk management in response to divergent sentiment.
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC Pharmaceuticals announced three poster presentations for the European Society for Medical Oncology (ESMO) Congress 2026. These presentations will highlight data from a Phase 1b trial of enozertinib in EGFR atypical NSCLC, the ongoing Phase 3 Himalayas-1 study of rinzimetostat in mCRPC, and preclinical data supporting rinzimetostat's mechanism of action. The congress will take place from October 23-27, 2026, in Madrid, Spain.
